Signal Management
Including signal detection, validation, prioritization, and assessment


Signal Management Services
ProPharma has deep expertise across all signal detection and management activities, including validation, prioritization, and assessment using data from a wide range of sources that are relevant for signal detection for the individual product(s). We are also fully trained and experienced in the EudraVigilance Data Analysis System (EVDAS) functionality and can support MAHs to comply with their obligations for signal detection and management. We leverage our robust knowledge to select the most efficient and effective method(s) for each product that is compliant with legislative requirements.
ProPharma's simple but scalable model of signal detection and management allows clients to obtain the exact services necessary throughout the entire life cycle of their products.
Signal management is a critical process for the proactive and timely identification of potential new safety risks for medicinal products that require the utmost expertise. Signal management can be deployed throughout both the clinical development and post-marketing phases of the product lifecycle. Safety issues may affect the benefit-risk balance of the product, requiring updates to product labels and other steps that help protect patients from harm.
Signal Detection in Pharmacovigilance
Signal detection in pharmacovigilance is the systematic process of identifying and evaluating potential safety signals in the data relating to a pharmaceutical product. This process involves scrutinizing various data sources for previously unrecognized adverse events or changes in patterns of known adverse events, which might be caused by a medicine. This is vital to monitor and assure the safety of a pharmaceutical product throughout its life cycle.
Key Steps in Signal Management
-
Signal Detection: Identifying potential safety signals using various data sources such as adverse event databases, literature, and other data.
-
Signal Validation: Verifying the identified signals to ensure they are genuine and warrant further investigation.
-
Signal Confirmation: Ensuring that the identified signal is supported by robust, scientific evidence.
-
Signal Assessment: Analyzing the available data to evaluate the relationship between the medicinal product and the observed risk and providing recommendations for mitigating risk to patient safety.
-
Communication: Working with the Client to inform regulatory authorities, healthcare professionals, patients, and the public about the findings and any new safety measures or recommendations resulting from signals in the management procedure.
-
Documentation: Recording all activities, assessments, decisions, and communications for accountability and future reference.
Significance of Signal Management

-
Patient Safety: Ensures that any potential safety concerns with pharmaceutical products are identified and managed to safeguard patients.
-
Regulatory Compliance: Ensures that regulatory requirements for monitoring and ensuring product safety are met.
-
Informed Decision Making: Helps healthcare professionals and patients make informed decisions about medicinal products.
-
Risk-Benefit Balance: Ensures that the benefits of a pharmaceutical product continue to outweigh its risks during the entire lifecycle.
How ProPharma Overcomes Signal Management Challenges
-
Data Quality: Defining robust strategies to analyze available data.
-
Timely Decision Making: Ensuring that decisions and communications are made in a timely manner to protect public health.
-
Global Consistency: Globally harmonized processes to collect, process, and assess data.

News & Insights

July 24, 2025
FDA Publishes over 200 Complete Response Letters (CRLs)
FDA's new transparency with over 200 CRLs empowers sponsors to navigate regulatory challenges more effectively, accelerating drug approvals and enhancing patient access to treatments.

July 24, 2025
Navigating EMA and Global Regulations for Medical Information Services
ProPharma guides clients through global medical information regulatory landscapes, ensuring compliance and excellence across markets with tailored solutions, AI integration, and continuous training.

July 8, 2025
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

July 8, 2025
From Drafts to First Patient in Record Time
Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...
.png?width=320&height=185&name=Successful%20Pre-IND%20Meetings%20WP%20(1).png)
June 23, 2025
FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...
A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

July 29, 2025
Avoiding Common Pitfalls During FDA Inspections
Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...
.png?width=320&height=185&name=labeling-webinar-thumbnail%20(1).png)
July 22, 2025
Inside FDA Review: Crafting a Quality ANDA Labeling Submission
Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...
News & Insights
.png?width=320&height=185&name=Successful%20Pre-IND%20Meetings%20WP%20(1).png)
June 23, 2025
FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...
A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...